Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02344069
Other study ID # PRooF-iTH
Secondary ID 2014-003978-16
Status Completed
Phase Phase 2
First received January 14, 2015
Last updated April 10, 2017
Start date February 2015
Est. completion date April 2017

Study information

Verified date April 2017
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Effect of immediate, pre-emptive fibrinogen concentrate in patients with trauma haemorrhage needing haemostatic resuscitation - a randomized, controlled, double-blinded investigator-initiated pilot trial


Description:

Objective To assess the efficacy and safety of an immediate pre-emptive first-line treatment with fibrinogen concentrate in patients with trauma haemorrhage in need of haemostatic resuscitation.

Hypothesis Immediate, pre-emptive first-line treatment of fibrinogen concentrate in trauma patients with ongoing critical haemorrhage will increase the clot strength.

Background Trauma haemorrhage remains a leading cause of morbidity and mortality. Fibrinogen is an essential endogenous component of haemostasis and the plasma level is associated to bleeding, transfusion and outcome.

Trial rationale Fibrinogen concentrate is widely used to correct acquired hypofibrinogenaemia, recommended by several international guidelines including in trauma, but evidence is lacking regarding the treatment safety and efficacy.

Trial population The trial population are patients' ≥ 18 years admitted to the Trauma Centre at Rigshospitalet with immediate need for blood transfusion at arrival and an expected need for haemostatic resuscitation with multiple transfusions during the initial resuscitation. Estimated 30-day mortality is 20 % in the population. Patients included in the trial will be temporarily incompetent because of acute, severe illness related to the ongoing critical bleeding needing multiple transfusion and immediate intervention to control bleeding.

Trial design This is a single centre, randomized (1:1, active:placebo), placebo controlled, double-blind investigator-initiated phase II trial in patients with traumatic, critical bleeding, investigating the safety and efficacy of immediate and pre-emptive administration of fibrinogen concentrate (Riastap®) or placebo as i.v infusion in 40 patients. All patients will receive standard of care including damage control surgery, radiological interventions and haemostatic resuscitation as part of their treatment at Rigshospitalet.

Patients considered to be included in the trial will be temporarily incompetent because of the acute, critical bleeding related to trauma, so scientific guardians will co-sign the informed consent form. Next-of-kin and the patients' general practitioner or the patients will co-sign as soon as possible.

During the study blood samples will be taken at different time points. Patients will be observed and assessed continuously throughout the first 72 hours. During the extended follow up period at day 30, contact will be made with the patients to follow up on safety events and establish potential mortality.

Investigational product Immediate intravenous administration as a single dose of fibrinogen concentrate (Riastap®, CSL Behring), when haemostatic resuscitation is deemed necessary by the clinician. The aim is to give the intervention < 1 hour of arrival, and the intervention should, when possible, be given prior to blood products.

Placebo and blinding Saline 0.9% will be used as placebo. The volume of placebo to be administered is equal to the volume active drug administered. The content (Riastap® or placebo) will be provided in opaque syringes and infusion sets (yellow-coloured) to disguise the content of the allocation to the treatment team.

Outcome measures

Primary outcome measure:

• Thrombelastograph (TEG®) Functional Fibrinogen (FF) maximum amplitude (MA) in mm at 15 min post intervention

Secondary outcome measures:

- TEG® FF MA in mm at 2, 6, 24 and 72 hours post intervention

- TEG® MA in mm at 15 min., 2, 6, 24 and 72 hours post intervention

- Transfusion requirements (Red blood cells (RBC) or fresh frozen plasma (FFP) or platelets (PLT)) at 2, 6, 24, 72 hours and in total at day 30

- Total use of haemostatic therapy (i.e. use of coagulation factor concentrates and tranexamic acid) in the first 24 and 72 hours, omitted from this is active treatment (intervention)

- Time to intervention or placebo

- Time to FFP and PLT transfusion

- Percentage of patients receiving intervention or placebo < 1 hour of arrival

- Time to surgical control of bleeding as noted by the surgeon

- Severe adverse reactions at day 30, defined as symptomatic thromboembolism at day 30 and anaphylaxis at day 30

- 24-hour and 30-day mortality


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date April 2017
Est. primary completion date March 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Trauma patient received directly from the scene of the accident AND

- Age = 18 years AND

- Initiated order of transfusion of at least one blood component within the 1st hour of arrival AND

- Predicted to need transfusion package therapy during the initial resuscitation (first 2 hours) AND

- Consent obtainable from patient or scientific guardians (independent physicians and/or next of kin

Exclusion Criteria:

- Duration of > 2 hours from time of accident to arrival at trauma centre OR

- Known anticoagulant treatment (vitamin K antagonist, dabigatran, rivaroxiban, apixaban) OR

- Severe isolated traumatic brain injury OR

- Moribund patient with devastating injuries and expected to die within one hour of admission OR

- Withdrawal from active therapy OR

- Previously, within 30 days, included in a randomized trial, if known at the time of enrolment OR

- Known body weight < 55 kg OR

- Any blood product prior to inclusion

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fibrinogen
Human fibrinogen concentrate as a injection
Placebo
Saline 0.9% as a injection

Locations

Country Name City State
Denmark Rigshospitalet, Copenhagen University Hospital Copenhagen

Sponsors (2)

Lead Sponsor Collaborator
Rigshospitalet, Denmark CSL Behring

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary TEG® Functional Fibrinogen maximum amplitude 15 min Thrombelastograph (TEG®) Functional Fibrinogen (FF) maximum amplitude (MA) in mm 15 min after intervention
Secondary TEG® Functional Fibrinogen maximum amplitude 2 hours Thrombelastograph (TEG®) Functional Fibrinogen (FF) maximum amplitude (MA) in mm 2 hours after intervention
Secondary TEG® Functional Fibrinogen maximum amplitude 6 hours Thrombelastograph (TEG®) Functional Fibrinogen (FF) maximum amplitude (MA) in mm 6 hours after intervention
Secondary TEG® Functional Fibrinogen maximum amplitude 24 hours Thrombelastograph (TEG®) Functional Fibrinogen (FF) maximum amplitude (MA) in mm 24 hours after intervention
Secondary TEG® Functional Fibrinogen maximum amplitude 72 hours Thrombelastograph (TEG®) Functional Fibrinogen (FF) maximum amplitude (MA) in mm 72 hours after intervention
Secondary TEG® maximum amplitude 15 min Thrombelastograph (TEG®) maximum amplitude (MA) in mm 15 min after intervention
Secondary TEG® maximum amplitude 2 hours Thrombelastograph (TEG®) maximum amplitude (MA) in mm 2 hours after intervention
Secondary TEG® maximum amplitude 6 hours Thrombelastograph (TEG®) maximum amplitude (MA) in mm 6 hours after intervention
Secondary TEG® maximum amplitude 24 hours Thrombelastograph (TEG®) maximum amplitude (MA) in mm 24 hours after intervention
Secondary TEG® maximum amplitude 72 hours Thrombelastograph (TEG®) maximum amplitude (MA) in mm 72 hours after intervention
Secondary Transfusions requirements Transfusion requirements (Red blood cells (RBC) or fresh frozen plasma (FFP) or platelets (PLT)) at 2, 6, 24, 72 hours and in total at day 30 2, 6, 24, 72 hours and in total at day 30
Secondary Total use of haemostatic therapy Total use of haemostatic therapy (i.e. use of coagulation factor concentrates and tranexamic acid) in the first 24 and 72 hours, omitted from this is active treatment (intervention) 24 hours and 27 hours
Secondary Time to intervention or placebo Time from arrival to active intervention or placebo in minutes No of minutes from arrival, an expected average of 45 minutes
Secondary Time to FFP and PLT transfusion Time to FFP and PLT transfusion in minutes No of minutes from arrival, an expected average of 50 minutes
Secondary Percentage of patients receiving intervention or placebo < 1 hour of arrival Percentage of patients receiving intervention or placebo < 1 hour of arrival 60 min from arrival
Secondary Time to surgical control of bleeding Time to surgical control of bleeding as noted by the surgeon No of minutes from arrival, an expected average of 120 minutes
Secondary Thromboembolism day 30 Symptomatic thromboembolism at day 30 (Severe adverse reaction) 30 days
Secondary Anaphylaxis day 30 Anaphylaxis day 30 (Severe adverse reaction) 30 days
Secondary 24-hour mortality Mortality in the first 24 hours 24 hours from arrival
Secondary 30-day mortality Mortality in the first 30 days 30 days from arrival
See also
  Status Clinical Trial Phase
Recruiting NCT04848376 - Post-Market Clinical Follow-up Study of A-SPINE's Products
Terminated NCT03781817 - Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children With Non-operative Fractures Phase 4
Completed NCT04342416 - Using a Brief Visuospatial Interference Intervention to Reduce Intrusive Memories Among Trauma Exposed Women N/A
Recruiting NCT04856449 - DBT Skills Plus EMDR for BPD and Trauma N/A
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Completed NCT05669313 - The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM
Active, not recruiting NCT03622632 - Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
Recruiting NCT04725721 - Testing FIRST in Youth Outpatient Psychotherapy N/A
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Not yet recruiting NCT03696563 - FreeO2 PreHospital - Automated Oxygen Titration vs Manual Titration According to the BLS-PCS N/A
Withdrawn NCT03249129 - Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma
Completed NCT02240732 - Surgical Tourniquets and Cerebral Emboli N/A
Completed NCT02227979 - Effects of PURPLE Cry Intervention N/A
Withdrawn NCT01169025 - Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients N/A
Recruiting NCT01812941 - Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients N/A
Completed NCT03112304 - Child STEPS for Youth Mental Health in Maine Sustainability N/A
Completed NCT01475344 - Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC) Phase 1/Phase 2
Completed NCT01201863 - Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy Phase 4
Completed NCT01210417 - Trauma Heart to Arm Time N/A